Beneficiary: Department of Pharmacy, University of Copenhagen, Denmark

Grant: DKK 40,000,000

Understanding how drugs interact with skin has long been a challenge within pharmaceutical research. Now, a new center at the Department of Pharmacy, UCPH, is set to become an international lighthouse in this research area, supported by a DKK 40 million grant from the LEO Foundation.

The LEO Foundation Center for Cutaneous Drug Delivery will form the basis of new research on skin and drugs. Behind the project is the Department of Pharmacy at the University of Copenhagen, where the center will also be located. The Director of the new center, Martin Malmsten, was formerly Head of Research at Uppsala University.

“I hope to contribute with my experience and thus help motivate and inspire colleagues and employees, enabling us to provide the best possible results. At the same time, I look forward to becoming part of the University of Copenhagen, where they have been very willing to prioritize strategic focus areas. The new center offers great and long-term opportunities for making an impact on international research and I’m happy to be part of this initiative, which will lift research in a very exciting area,” said Martin Malmsten.

The LEO Foundation Center for Cutaneous Drug Delivery will conduct research on what happens in and on the skin when we apply drugs. There will be a particular focus on the physical-chemical aspects of the interaction between skin and drugs, which is important to the development of new drugs. This will hopefully help optimize the drug properties and allow for maximum utilization while simultaneously minimizing side effects.

“Our new center meets a huge demand for understanding how drugs interact with skin. With a strong team of highly qualified researchers, we will set new standards for research in the field of dermatology and I’m both proud and grateful that this grant from the LEO Foundation has helped us attract new and strong forces to UCPH. This new strategic effort will benefit patients as well as society in general,” said Dean Ulla Wewer from the Department of Health and Medical Sciences at the University of Copenhagen.

Generating new knowledge while also providing a space for innovative research methods and new analytical technologies is what the center aims for. The LEO Foundation has backed the center with a grant of DKK 40 million over the next ten years, which in itself is quite remarkable.

“We’re very happy to support this important initiative and the grant of DKK 40 million over the next ten years is the single largest grant the foundation has ever awarded. What’s more important, however, is the fact that we are quite convinced that the center with its strong team of researchers has the potential to become a global powerhouse in terms of research on the dynamic interaction between drugs and skin,” said Lars Olsen, Chairman of the LEO Foundation.

Beneficiary: LEO Pharma Research Foundation, Ballerup, Denmark

Grant: EUR 120,000

The LEO Pharma Research Foundation (LPRF) has supported research within medicine, chemistry, biology and pharmacy throughout the years. The LEO Pharma Research Foundation is separate from the LEO Foundation, as well as the rest of LEO Pharma, and has its own board.

Every year, LPRF presents gold and silver awards to talented and committed young researchers in recognition of their exceptional contribution to science. Candidates are selected in association with the European Society for Dermatological Research (ESDR).

The LEO Foundation sponsors LPRF’s award symposium, which takes place at ESDR’s Annual General Meeting and typically features scientific presentations from the two award winners and a keynote speaker.

ESDR homepage

Beneficiaries: Dr. Richard H. Guy, Professor of Pharmaceutical Sciences & Dr. M. Begona Delgado-Charro, Associate Professor of Pharmaceutics, University of Bath, UK

Grant: DKK 3,564,000

The project aims to develop a physiologically based pharmacokinetic model to predict the dermal absorption and disposition of drugs included in complex topical products.

A distinctive feature of the research is the integration of formulation-dependent information derived experimentally, and a deliberate strategy to facilitate the practical implementation of the model for a wide range of drugs.

The long-term goal is to develop a model, which will predict drug absorption and disposition from dermal products thereby facilitating their optimisation and, ultimately, the development of high-performance medicines.

Beneficiary: Mikkel Bohm, Young Scientists (Astra)

Grant: DKK 3,000,000

The talent competition, Young Scientists, is developing talents in both kids and young people in science.

It is believed that science is a powerful tool to understand and change the world for the better. The competition’s aim is to contribute to society in a meaningful way by inspiring a new generation and giving them engaging experiences with science.

The LEO Foundation has found this work important and supports the competition over three years.

Beneficiaries: Amy Paller, MS, MD, IEC President, Professor of Dermatology and Professor of Pediatrics, Northwestern University’s Feinberg School of Medicine, Chicago, IL, USA, and Emma Guttman-Yassky, MD, PhD, IEC President-Elect, Associate Professor of Dermatology & Immunology, Department of Dermatology, Icahn School of Medicine, Mount Sinai, New York, NY, USA

Grant: DKK 340,000

The IEC is convening a meeting at the ESDR in September 2015 to write a position paper on Atopic Dermatitis as a systemic disease.

In March 2016, the IEC will hold a session at the Annual AAD in Washington, D.C. focusing on AD phenotyping – starting to use biomarkers to assess subgroups of AD, which may be relevant to the understanding of disease and treatment decision-making.

Beneficiary: Associate Professor Kiarash Khosrotehrani, University of Queensland, Australia

Grant: AUD 415,386

In this study, Associate Professor Kiarash Khosrotehrani of The University of Queensland in Australia proposes to better characterise the molecular nature of the factors provided by fibroblasts to support basal cell carcinoma (BCC) growth in vivo in order to find new targets for therapies that would prevent BCC development. He and his team will also show proof of principle demonstrating that targeting this process can actually prevent BCC development.

These findings have the potential to translate in effective prevention strategies, allowing field therapy of normal looking skin to avoid the development of new BCCs. Such finding will have strong health benefits in terms of morbidity associated with multiple surgeries, years of healthy life enjoyed by individuals and finally in terms of economic cost.

Beneficiary: Associate Professor Kiarash Khosrotehrani, University of Queensland, Australia

Grant: AUD 268,239

Associate Professor Kiarash Khosrotehrani from The University of Queensland leads a team that has hypothesized that upon UV irradiation and acquisitions of mutations, only epidermal cells that can rapidly proliferate are likely to give rise to pre-cancerous and cancerous lesions.

This hypothesis will be tested using multicolour lineage tracing to follow simultaneously multiple epidermal clones that will further be microdissected to establish their mutational profile.  This study has the potential to fundamentally change our understanding of field cancerisation, cell of origin of squamous cell cancer establishing potentially new therapeutic targets.

Beneficiary: The HOME Group

Grant: DKK 310,000

Despite the high burden of atopic eczema, evidence-based clinical care and decision-making (i.e. comparison of treatment results) is currently limited by the use of multiple un-validated outcome measures (i.e. disease severity scales).

In response to this situation, the HOME initiative was formed in 2008, among other to: facilitate an international, multi-disciplinary consensus on core outcome measures to be included in all eczema trials and clinical record keeping.

The HOME initiative is an international group working together to agree on core outcome measures for atopic eczema clinical trials. Participation in HOME is open to anyone with an interest in outcomes for atopic eczema. Further information can be found via….

Beneficiaries: Ida Marie Heerfordt & Hans Christian Wulf of Bispebjerg University Hospital in Copenhagen, Denmark

Grant: DKK 456,169

There is a significant clinical need for a more objective and reproducible assessment of AK thickness, severity either in different classes or even better as a continuum. Furthermore it would be valuable to link such assessment with histology and if feasible link with risk of progression as well as potential response to treatment.

The methods to be used by Ida Marie Heerfordt and Hans Christian Wulf of Bispebjerg University Hospital in Copenhagen, Denmark, will be to test various diagnostics (measuring skin capacitance, resistance, etc.) and link to clinical presentation, objective measurement of thickness, using a new scale tool and histology.